MGNX stock forecast, quote, news & analysis
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer... Show more
Why MacroGenics (MGNX) Stock Is Down -20% in the Last 30 Days
Key Takeaways
- MacroGenics (MGNX) shares fell approximately 20% over the past 30 days, declining from $4.81 on June 26, 2026, to $3.84 on July 28, 2026.
- The stock rallied sharply earlier in the quarter following the May 2026 announcement of the $122.5 million manufacturing asset sale to Bora Pharmaceuticals, but has since given back a significant portion of those gains.
- A July 23 clinical update on the Phase 1 study of MGC026, the company's B7-H3-targeted antibody-drug conjugate, coincided with a pronounced single-day sell-off on July 24.
- Despite the recent pullback, MGNX remains up roughly 27% over the full quarter, supported by the Bora transaction close and a $24.5 million regulatory milestone payment from Sanofi.
- Analyst commentary has been mixed: B.Riley upgraded the stock to Buy with a $9 price target earlier in 2026, while Citizens JMP reiterated a Market Perform rating on July 27, 2026, noting the stock trades at a discount to pro forma cash.
MacroGenics (MGNX) Company Overview and Market Position
MacroGenics is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. The company leverages its proprietary suite of next-generation antibody technology platforms, including its Dual-Affinity Re-Targeting (DART) and antibody-drug conjugate (ADC) platforms, to build a pipeline of product candidates. Its clinical-stage assets include lorigerlimab, a bispecific PD-1/CTLA-4 DART molecule; MGC026, an ADC targeting B7-H3; and MGC028, an ADC targeting ADAM9. MacroGenics also holds royalty interests in commercial-stage products including ZYNYZ (retifanlimab) and TZIELD (teplizumab), providing non-dilutive revenue streams. Strategic collaborations with global pharmaceutical companies such as Sanofi underscore the company's position in the immuno-oncology space.
MacroGenics (MGNX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MGNX shares declined roughly 20%, sliding from a closing price of $4.81 on June 26, 2026, to $3.84 during intraday trading on July 28, 2026. The downtrend accelerated in the second half of July, with the stock falling below the $4.00 threshold on July 24 in a session marked by elevated trading volume of approximately 1.5 million shares, well above the 30-day average.
In contrast, the broader quarterly performance tells a different story. MacroGenics opened the quarter near $3.01 on April 28, 2026, and surged in mid-May following the announcement of the Bora Pharmaceuticals manufacturing asset sale. The stock reached a quarterly peak around $4.86 on June 29 before entering its current pullback phase. As of July 28, MGNX retained a quarterly gain of approximately 27%, reflecting the positive initial reaction to the strategic divestiture and improved balance sheet metrics.
What Drove MGNX Stock Price in the Last 30 Days
Several verified factors contributed to the stock's 20% decline over the past month. The completion of the Bora Pharmaceuticals transaction on July 2, 2026, which delivered $122.5 million in cash to MacroGenics, initially supported the stock near the $4.70 level. However, a classic "sell the news" pattern emerged in the weeks that followed, as investors locked in profits from the strong rally that began in mid-May.
The most significant downward catalyst occurred on July 23, 2026, when MacroGenics issued a clinical update on the ongoing Phase 1 study of MGC026, its B7-H3-targeted ADC. The company announced that dose escalation had progressed and the trial had entered dose expansion, with a focus on small cell carcinoma of the head and neck. The market's reaction on July 24 was sharply negative, with shares dropping from $4.01 to $3.70 on heavy volume, suggesting investors may have been hoping for more definitive early efficacy signals. On July 27, Citizens JMP reiterated a Market Perform rating, observing that the stock was trading at an approximately 30% discount to pro forma cash of around $328 million, while characterizing the discount as consistent with other biotechnology companies facing similar pipeline uncertainties.
What Drove MGNX Stock Performance Over the Last Quarter
The quarter's defining catalyst was the May 11, 2026, announcement that Bora Pharmaceuticals would acquire MacroGenics' GMP drug substance manufacturing operations for $122.5 million. The news triggered an immediate re-rating of the stock, which surged from roughly $2.95 to above $4.00 within days. The transaction, which closed on July 2, transformed MacroGenics' balance sheet by significantly bolstering its cash position while also reducing operational complexity.
Additional tailwinds during the quarter included a $24.5 million regulatory milestone payment from Sanofi following the FDA's accelerated approval of TZIELD for delaying the decline in endogenous insulin production in children with stage 3 type 1 diabetes. MacroGenics also expanded a royalty purchase agreement with Sagard, securing a $60 million upfront payment for a capped royalty interest on future global net sales of ZYNYZ. Earlier in 2026, B.Riley upgraded MGNX from Neutral to Buy with a $9.00 price target, reflecting optimism around the company's ADAM9 TOPO1i antibody-drug conjugate program. These positive developments, however, have been partially offset by the recent MGC026 clinical update and broader biotech sector volatility.
Trending AI Robots
For traders seeking data-driven approaches to navigate volatile biotechnology stocks like MacroGenics, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of algorithmic trading bots that monitor thousands of tickers across diverse market sectors, but only the top-performing and most relevant strategies are featured in this section. Each bot operates with distinct parameters, including varying timeframes, risk profiles, and strategy types — from swing trading to longer-term trend following. The curated Trending AI Robots page allows investors to quickly evaluate which automated strategies are currently generating the strongest signals, offering a practical starting point for those interested in incorporating AI-driven insights into their trading workflow.
MGNX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most significant catalyst for MGNX will be the presentation of initial human data for MGC026 at ESMO 2026 in Madrid, where MacroGenics plans to share clinical results from the Phase 1 study alongside data from the LINNET study of lorigerlimab in prostate and colorectal cancer. Analysts at Citizens JMP have indicated these data could address key investor questions about MacroGenics' future trajectory. Beyond clinical readouts, investors should monitor the company's cash runway following the Bora transaction proceeds and Sanofi milestone, as well as potential further monetization of royalty interests. Competitive developments in the ADC and bispecific antibody spaces, regulatory decisions affecting partnered products, and broader macroeconomic conditions impacting the biotechnology sector will also influence MGNX's price action in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MGNX in upward trend: price may jump up because it broke its lower Bollinger Band on July 23, 2026
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where MGNX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Bearish Trend Analysis
The 10-day RSI Indicator for MGNX moved out of overbought territory on June 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on July 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
MGNX moved below its 50-day moving average on July 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MGNX entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.062) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (1.486) is also within normal values, averaging (420.906).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology